Cannell Capital’s Journey Medical DERM Stock Holding History

Cannell Capital’s Portfolio DERM Stock Details DERM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-41,108	Closed	-$221K	–	74
2021 Q4	$221K	Buy	+41,108	New	+$298K	0.04%	62

Other funds holding DERM

BRF

B. Riley Financial Los Angeles, California $456M AUM 896.07% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

AFG

American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return

MAG

Millrace Asset Group Berwyn, Pennsylvania $98.4M AUM 63.71% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Cannell Capital's DERM Position: Q1 2022 in Review

Cannell Capital sold out of Journey Medical (DERM) in Q1 2022, closing a stake of 41,108 shares — an estimated $221K sold.

Cannell Capital first reported a position in DERM in Q4 2021 and held it in 1 quarter. The position peaked at $221K in Q4 2021. 14 funds tracked by Wall St. Rank hold DERM as of Q1 2022.

Cannell Capital reported no remaining Journey Medical position as of Q1 2022 after selling out during the quarter.
Cannell Capital sold 41,108 Journey Medical shares in Q1 2022, an estimated $221K.
Cannell Capital first reported a position in Journey Medical in Q4 2021 and held it in 1 quarter.
Cannell Capital's Journey Medical position peaked at $221K in Q4 2021.
14 funds tracked by Wall St. Rank held Journey Medical as of Q1 2022.

Based on Cannell Capital's 13F filing for Q1 2022, filed 17 May 2022.